318|3|Public
25|$|<b>Primidone,</b> reduces plasma {{levels of}} <b>primidone.</b> Hence {{reducing}} anticonvulsant effect.|$|E
25|$|Open-label {{case series}} have {{suggested}} that <b>primidone</b> is effective {{in the treatment of}} epilepsy. <b>Primidone</b> has been compared to phenytoin, phenobarbital, mephobarbital, ethotoin, metharbital, and mephenytoin. In adult comparison trials, <b>primidone</b> {{has been found to be}} just as effective.|$|E
25|$|Additionally, a {{coagulation}} defect resembling Vitamin K deficiency {{has been}} observed in newborns of mothers taking <b>primidone.</b> Because of this, <b>primidone</b> is a Category D medication.|$|E
25|$|The exact {{mechanism}} of <b>primidone's</b> anticonvulsant action is still unknown after over fifty years. It {{is believed to}} work via interactions with voltage-gated sodium channels which inhibit high-frequency repetitive firing of action potentials.|$|R
25|$|It {{was first}} {{reported}} to exacerbate hepatic porphyria in 1975. In 1981, {{it was shown}} that phenobarbital, one of <b>primidone's</b> metabolites, only induced a significant porphyrin at high concentrations in vitro. It can also cause elevations in hepatic enzymes such as gamma-glutamyl transferase and alkaline phosphatase.|$|R
25|$|By 1980, <b>primidone</b> {{was seen}} as not worth {{mentioning}} as an option for childhood temporal lobe epilepsy by doctors in the United Kingdom. In January 1981, Dr. O'Brien and colleagues reported that <b>primidone</b> had {{a positive effect on}} the essential tremor of one of their patients. This led them to initiate a twenty-person prospective study. Twelve of the participants responded well. By 1984, valproic acid was the drug of choice for juvenile myoclonic epilepsy and not the equally effective <b>primidone.</b> However, as late as 1985, <b>primidone</b> was {{still one of the most}} widely used anticonvulsants. At the close of the 1980s, <b>primidone</b> was still the preferred anticonvulsant for complex partial seizures in Germany. In 1989, Dainippon Pharmaceutical launched Exegran (zonisamide), the first new, chemically unique, non-benzodiazepine anticonvulsant in decades.|$|E
25|$|<b>Primidone</b> {{has been}} used in {{cerebral}} palsy. In 1953, Plum and Sparup found that out of thirty-three patients, twenty had a favorable or moderate response. Thorn reported in 1962 that sixteen patients responded favorably to both <b>primidone</b> and chlordiazepoxide and four to only <b>primidone.</b> Nine patients responded only to chlordiazepoxide and four responded to neither drug. The best results were obtained in athetosis and rigidity.|$|E
25|$|The {{most common}} {{symptoms}} of <b>primidone</b> overdose are coma with loss of deep tendon reflexes and, during the recovery period, {{if the patient}} survives, disorientation, dysarthria, nystagmus, and ataxia, lethargy, somnolence, vomiting, nausea, and occasionally, focal neurological deficits which lessen over time. Complete recovery comes within five to seven days of ingestion. The symptoms of <b>primidone</b> poisoning have generally been attributed to its biotransformation to phenobarbital; however, <b>primidone</b> has toxic effects independent of its metabolites in humans. The massive crystalluria that sometimes occurs sets its symptom profile apart from that of phenobarbital. The crystals are white, needle-like, shimmering, hexagonal plates consisting mainly of <b>primidone.</b>|$|E
25|$|In {{the three}} {{adults who are}} {{reported}} to have succumbed, the doses were 20–30 g. However, two adult survivors ingested 30 g 25 g, and 22.5 g. One woman experienced symptoms of <b>primidone</b> intoxication after ingesting 750mg of her roommate's <b>primidone.</b>|$|E
25|$|Hyperammonemic {{encephalopathy}} {{was reported}} by Katano Hiroyuki of the Nagoya City Higashi General Hospital in early 2002 in a patient who had been stable on <b>primidone</b> monotherapy for five years before undergoing surgery for astrocytoma, a type of brain tumor. Additionally, her phenobarbital levels were inexplicably elevated post-surgery. This is much more common with the valproates than {{with any of the}} barbiturates. A randomized controlled trial whose results were published in the July 1985 issue of The New England Journal of Medicine found that <b>primidone</b> was more likely to cause impotence than phenytoin, carbamazepine, or phenobarbital. Like phenytoin, <b>primidone</b> is rarely associated with lymphadenopathy. <b>Primidone</b> can also cause vomiting; this happens in 1.0–0.1% of users.|$|E
25|$|Barbiturates {{including}} thiopental, phenobarbital, <b>primidone,</b> etc.|$|E
25|$|Less than 1% of <b>primidone</b> {{users will}} {{experience}} a rash. Compared to carbamazepine, lamotrigine, and phenytoin, {{this is very}} low. The rate is {{comparable to that of}} felbamate, vigabatrin, and topiramate. <b>Primidone</b> also causes exfoliative dermatitis, Stevens–Johnson syndrome, and toxic epidermal necrolysis.|$|E
25|$|Clonazepam {{increases}} {{the levels of}} <b>primidone</b> and phenobarbital.|$|E
25|$|Two {{trials of}} <b>primidone</b> for {{athetosis}} have been published. In one, small doses of <b>primidone</b> successfully treated eighteen out of thirty-one children. In a subsequent pilot trial {{in which children}} who experienced improvement were switched to placebo, the results were much more disappointing, with the two subjects who experienced subjective improvement also experiencing this on placebo.|$|E
25|$|The {{effect of}} <b>primidone</b> in {{essential}} tremor is not mediated by PEMA.|$|E
25|$|In March 1993, S.G. Hayes of the University of Southern California School of Medicine {{reported}} that {{nine out of}} twenty-seven people (33%) with either treatment-resistant depression or treatment-resistant bipolar disorder had a permanent positive response to <b>primidone.</b> It {{should be noted that}} a plurality of subjects were also given methylphenobarbital in addition to or instead of <b>primidone.</b>|$|E
25|$|The {{second case}} report, {{published}} in the December 1986 issue of Zhonghua Xin Xue Guan Bing Za Zhi, describes four cases, men, women, adults and adolescents, who were put on <b>primidone</b> for LQTS. The 2002 case focuses on hypocalcemia stemming from such treatment in an adolescent male. The <b>primidone</b> he had been taking suppressed his hypocalcemia-induced QT prolongation.|$|E
25|$|In May 2005, Dr. M. Lopez-Gomez's team {{reported}} {{an association between}} the use of <b>primidone</b> and depression in epilepsy patients; this same study reported that inadequate seizure control, posttraumatic epilepsy, and polytherapy were also risk factors. Polytherapy was also associated with poor seizure control. Out of all of the risk factors, usage of <b>primidone</b> and inadequate seizure control were the greatest; with ORs of 4.089 and 3.084, respectively. They had been looking for factors associated with depression in epilepsy patients. Schaffer et al. 1999 reported that one of their treatment failures, a 45-year-old woman taking 50mg a day along with lithium 600mg/day, clozapine 12.5mg/day, trazodone 50mg/day, and alprazolam 4mg/day {{for three and a half}} months experienced auditory hallucinations that led to discontinuation of <b>primidone.</b> It can also cause hyperactivity in children; this most commonly occurs at low serum levels. There is one case of an individual developing catatonic schizophrenia when her serum concentration of <b>primidone</b> went above normal.|$|E
25|$|In the Netherlands alone, {{there were}} thirty-four cases of {{suspected}} <b>primidone</b> poisoning between 1978 and 1982. Out of these, <b>Primidone</b> poisoning {{was much less}} common than phenobarbital poisoning. Twenty-seven of those adult cases were reported to the Dutch National Poison Control Center. Out of these, one person taking it with phenytoin and phenobarbital died, twelve became drowsy and four were comatose.|$|E
25|$|The {{percentage}} of <b>primidone</b> converted to phenobarbital {{has been estimated}} to be 5% in dogs and 15% in humans. Work done twelve years later found that the serum phenobarbital 0.111mg/100 mL for every mg/kg of <b>primidone</b> ingested. Authors publishing a year earlier estimated that 24.5% of <b>primidone</b> was metabolized to phenobarbital. However, the patient reported by Kappy and Buckley {{would have had a}} serum level of 44.4mg/100 mL instead of 8.5mg/100 mL if this were true for individuals who have ingested large dose. The patient reported by Morley and Wynne would have had serum barbiturate levels of 50mg/100 mL, which would have been fatal.|$|E
25|$|Mesuximide {{increases}} plasma {{levels of}} phenobarbital in <b>primidone</b> users, both <b>primidone</b> and phenobarbital accelerate the metabolism of carbamazepine via CYP3A4, and lamotrigine's apparent clearance is increased by <b>primidone.</b> In {{addition to being}} an inducer of CYP3A4, {{it is also an}} inducer of CYP1A2, which causes it to interact with substrates such as fluvoxamine, clozapine, olanzapine, and tricyclic antidepressants. It also interacts with CYP2B6 substrates such as bupropion, efavirenz, promethazine, selegiline, and sertraline; CYP2C8 substrates such as amiodarone, paclitaxel, pioglitazone, repaglinide, and rosiglitazone; and CYP2C9 substrates such as bosentan, celecoxib, dapsone, fluoxetine, glimepiride, glipizide, losartan, montelukast, nateglinide, paclitaxel, phenytoin, sulfonamides, trimethoprim, warfarin, and zafirlukast. It also interacts with estrogens.|$|E
25|$|<b>Primidone</b> is not {{the only}} {{anticonvulsant}} used for essential tremor; the others include topiramate (Topamax) and gabapentin (Neurontin). Other pharmacological agents include alprazolam (Xanax), clonazepam (Klonopin), atenolol, sotalol, nadolol, clozapine, nimodipine, and botilinum toxin A. Many of these drugs were less effective (according to Table 1), but a few were not. Only propranolol has been compared to <b>primidone</b> in a clinical trial.|$|E
25|$|The rate of {{metabolism}} of <b>primidone</b> into phenobarbital was {{inversely related}} to age; the highest rates were in the oldest patients (the maximum age being 55). People aged 70–81, relative to people aged 18–26, have decreased renal clearance of <b>primidone,</b> phenobarbital, and PEMA, in ascending order of significance, {{and that there was}} a greater proportion of PEMA in the urine. The clinical significance is unknown.|$|E
25|$|Unlike carbamazepine, {{there are}} few case reports {{mentioning}} the use of <b>primidone</b> {{in the treatment of}} trigeminal neuralgia. The first, published in the October 10, 1957 issue of Gazette Médicale de France, has no abstract. The second one was a case report of a woman taking <b>primidone</b> and then phenobarbital for trigeminal neuralgia. She developed toxic epidermal necrolysis, as well as endocarditis and gastrointestinal hemorrhage. The second recurrence, induced by phenobarbital, killed her within five weeks of onset.|$|E
25|$|<b>Primidone</b> has {{veterinary}} uses, {{including the}} prevention of aggressive behavior and cannibalism in gilt pigs, and treatment of nervous disorders in dogs and other animals.|$|E
25|$|Many of {{the drugs}} used for myoclonus, such as barbiturates, {{phenytoin}} and <b>primidone,</b> are also used to treat epilepsy. Barbiturates slow down {{the central nervous system}} and cause tranquilizing or antiseizure effects. Phenytoin and <b>primidone</b> are effective antiepileptics drugs, although phenytoin can cause liver failure or have other harmful long-term effects in patients with PME. Sodium valproate is an alternative therapy for myoclonus and can be used either alone or in combination with clonazepam. Some people have adverse reactions to clonazepam and/or sodium valproate.|$|E
25|$|<b>Primidone</b> {{has other}} {{cardiovascular}} effects in beyond shortening the QT interval. Both it and phenobarbital {{are associated with}} elevated serum levels (both fasting and six hours after methionine loading) of homocysteine, an amino acid derived from methionine. This is almost certainly related to the low folate levels reported in <b>primidone</b> users. Elevated levels of homocysteine {{have been linked to}} coronary heart disease. In 1985, both drugs were also reported to increase serum levels of high density lipoprotein (HDL) cholesterol, total cholesterol, and apolipoproteins A and B.|$|E
25|$|Treatments for <b>primidone</b> {{overdose}} {{have included}} hemoperfusion with forced diuresis, {{a combination of}} bemegride and amiphenazole; and a combination of bemegride, spironolactone, caffeine, pentylenetetrazol, strophanthin, penicillin and streptomycin.|$|E
25|$|<b>Primidone</b> is {{available}} as a 250mg/5mL suspension, and {{in the form of}} 50mg, 125mg, and 250mg tablets. It is also available in a chewable tablet formulation in Canada.|$|E
25|$|<b>Primidone</b> {{is one of}} the {{anticonvulsants}} {{associated with}} anticonvulsant hypersensitivity syndrome, others being carbamazepine, phenytoin, and phenobarbital. This syndrome consists of fever, rash, peripheral leukocytosis, lymphadenopathy, and occasionally hepatic necrosis.|$|E
25|$|The {{first case}} report {{in which the}} {{shortening}} of the QT interval by <b>primidone</b> was documented, published in the July 1980 issue of Annals of Internal Medicine, involved three patients, a 31-year-old woman, her 15-year-old nephew, and his 16-year-old sister. The woman still had ventricular fibrillation, syncope, and seizures even after the removal of her left stellate ganglion and a thoracic chain dissection. The woman had previously been tried {{on a combination of}} phenobarbital and phenytoin when she was thought to have only seizures, followed by phenobarbital combined phenytoin and procainamide. The procainamide was replaced with propanolol, which in turn replaced the propanolol when the latter brought the tachycardia back almost instantaneously upon the first dose. The phenobarbital and phenytoin were then combined with atropine and acetyl strophanthidin. When this failed, the atropine and acetyl strophanthidin were replaced with lidocaine prior to the surgery. After the surgery, the QT-prolongation returned, so the phenytoin was doubled to 200mg four times daily. A month later, she was admitted to the hospital for phenytoin toxicity, where it was found that she had slow spike and abortive wave activity in her left temporal lobe. It was after this that <b>primidone</b> was substituted for phenytoin. The <b>primidone</b> suppressed the fibrillations and lengthened the QT interval for two years and eight months in the patient. Her 16-year-old niece was started on <b>primidone</b> after an unsuccessful trial of phenytoin. Following this, her 15-year-old nephew, the niece's brother, was started because of family history.|$|E
25|$|<b>Primidone</b> {{can cause}} drowsiness, listlessness, ataxia, visual disturbances, nystagmus, headache, and dizziness. These side effects {{are the most}} common, {{occurring}} in more than 1% of users. Transient nausea and vomiting are also common side effects.|$|E
25|$|<b>Primidone,</b> like {{phenobarbital}} and the benzodiazepines, {{can also}} cause sedation in the newborn and also withdrawal within {{the first few days}} of life; phenobarbital is the most likely out of all of them to do that.|$|E
25|$|The major metabolite, phenobarbital, is also {{a potent}} {{anticonvulsant}} {{in its own right}} and likely contributes to primidone's effects in many forms of epilepsy. According to Brenner's Pharmacology textbook, <b>Primidone</b> also increases GABA-mediated chloride flux: thereby hyperpolarizing the membrane potential.|$|E
25|$|<b>Primidone</b> and {{the other}} enzyme-inducing {{anticonvulsants}} can cut the half-life of antipyrine roughly in half (6.2 ± 1.9 h vs. 11.2 ± 4.2 h), and increases the clearance rate by almost 70%. Phenobarbital reduces the half-life to 4.8 ± 1.3 and increases the clearance by almost 109%. It also interferes with the metabolism of dexamethasone, a synthetic steroid hormone, {{to the point where}} its withdrawal from the regimen of a 14-year-old living in the United Kingdom made her hypercortisolemic. Tempelhoff and colleagues at the Washington University School of Medicine's Department of Anesthesiology reported in 1990 that <b>primidone</b> and other anticonvulsant drugs increase the amount of fentanyl needed during craniotomy based on the patient's heart rate.|$|E
25|$|Barbiturates such as {{phenobarbital}} {{were long}} used as anxiolytics and hypnotics, but today {{have been largely}} replaced by benzodiazepines for these purposes because the latter are less toxic in overdose. However, barbiturates are still used as anticonvulsants (e.g., phenobarbital and <b>primidone)</b> and general anesthetics (e.g., sodium thiopental).|$|E
